CN Innovations
VC Fund
Hong Kong, Hong Kong
CN Innovations is a science-based technology and precision engineering company. CN Innovations Holdings provides OEM technical and supply chain solutions to major industries.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries CN Innovations invests in
Stages CN Innovations invests in
Countries CN Innovations invests in
Investment Focus
Industry
- Energy 1 (20%)
- Medical 1 (20%)
- Biopharma 1 (20%)
- Fuel Cell 1 (20%)
- Wearables 1 (20%)
Stage
- Seed 2 (40%)
- Series A 1 (20%)
- Series B 1 (20%)
- Venture - Series Unknown 1 (20%)
Country
- Hong Kong 1 (20%)
- United States 1 (20%)
- United Kingdom 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based onthe culture of primary human hepatocytes in the company’s proprietary LiverChip® platform. The HBV disease model, which is referred to as Quantum-B®, is currently being deployed in drug discovery and research alliances with a number of leading pharmaceutical and biotech companies.Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next generation organ-on-chips which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market. | $21M / Series B / Apr 23, 2024 | ||
| Versogen develops electrolyzer technology for water and renewable energy to produce green hydrogen at scale. The company produces high-performing hydroxide exchange membranes for a variety of applications, such as lowering the production costs of fuel cells and reducing industrial carbon emissions, and laying the foundation for a sustainable energyfuture. | $14.5M / Series A / May 10, 2022 | ||
| CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based onthe culture of primary human hepatocytes in the company’s proprietary LiverChip® platform. The HBV disease model, which is referred to as Quantum-B®, is currently being deployed in drug discovery and research alliances with a number of leading pharmaceutical and biotech companies.Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next generation organ-on-chips which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market. | $9M / Venture - Series Unknown / Mar 02, 2020 | ||
| Redefining the mobile computing experience through screen-free, voice and gesture-based products and services. | $510K / Seed / Jan 10, 2017 | ||
| CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based onthe culture of primary human hepatocytes in the company’s proprietary LiverChip® platform. The HBV disease model, which is referred to as Quantum-B®, is currently being deployed in drug discovery and research alliances with a number of leading pharmaceutical and biotech companies.Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next generation organ-on-chips which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market. | Seed |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does CN Innovations invest in?
CN Innovations invests primarily in Energy, Medical and Biopharma startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in Hong Kong. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did CN Innovations last invest?
The most recent investment recorded for CN Innovations closed in Apr 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
